Heart Disease News and Research

Latest Heart Disease News and Research

TPI announces formulation expansion program for GMOL

Tianyin Pharmaceutical Co., Inc., a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine (TCM), branded generics and active pharmaceutical ingredients (API) today announced the formulation expansion program for its flagship product Gingko Mihuan Oral Liquid.

4 Nov 2011

Sensor system can monitor heart rate, skin conductance while driving

Safety in traffic depends on a number of factors. One decisive aspect is how fit the driver is. A research team at the Technische Universitaet Muenchen (TUM), in collaboration with researchers at the BMW Group, managed to develop a sensor system integrated into the steering wheel that can monitor the driver's state of health while driving.

4 Nov 2011

FDA accepts VIVUS' Qnexa NDA for filing and review

VIVUS, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the New Drug Application (NDA) for Qnexa to treat obesity. The company resubmitted the NDA on October 17, 2011.

4 Nov 2011

Scientists identify gene responsible for abdominal aortic aneurysms

Medical scientists have for the first time identified a gene responsible for a fatal abdominal condition that afflicts tens of thousands of people across the world.

4 Nov 2011

Merck’s cholesterol lowering drug gets FDA panel’s vote

A health advisors’ panel have unanimously backed the use of Merck & Co's cholesterol-lowering drug Vytorin for preventing stroke and other heart problems in patients with chronic kidney disease, but only in those patients not yet on dialysis. The panel voted 16-0 during a meeting today in Silver Spring, Maryland.

3 Nov 2011

Edwards Life Sciences heart valve approved in the US

The U.S. Food and Drug Administration (FDA) this Wednesday approved the sale of Edwards Life Sciences Corp's Sapien heart valve for patients deemed too sick to have open-heart surgery.

3 Nov 2011

The brain and the heart may not be so different after all

What do heart disease and dementia have in common? Perhaps more than meets the eye, according to researchers at the University of Rochester Medical Center.

3 Nov 2011

POZEN third quarter revenue increases to $4.9 million

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the third quarter ended September 30, 2011.

3 Nov 2011

First Edition: November 3, 2011

Today's headlines include reports about a bipartisan group of lawmakers who are urging the super committee to consider "all options."

3 Nov 2011

Abiomed second quarter revenue increases 26% to $29.5 million

Abiomed, Inc., a leading provider of breakthrough heart support technologies, today reported second quarter fiscal 2012 revenue of $29.5 million, up 26% compared to revenue of $23.4 million in the same period of fiscal 2011.

3 Nov 2011

Cancer responsible for 40% of all premature deaths

Cancer is responsible for killing 40 per cent of all the men and women who die prematurely between the ages of 25 and 74 in the UK - according to a new analysis of the figures released today by Cancer Research UK.

3 Nov 2011

Study assesses value of current scenario-based training programs for firefighters

Current training programs may not effectively prepare firefighters for the range of scenarios they are likely to encounter, according to human factors/ergonomics researchers Michael R. Baumann, Carol L. Gohm, and Bryan L. Bonner.

3 Nov 2011

JDC receives NIDDK grant for research into diabetic retinopathy, kidney disease

Joslin Diabetes Center has received a $3.9 million DP3 grant from the National Institute of Diabetes and Digestive and Kidney Diseases, part of the National Institutes of Health, to identify protective factors that enable many Joslin 50-Year Medalists to remain free of commonly occurring diabetes complications.

3 Nov 2011

FDA EMDAC votes to recommend approval of Merck's VYTORIN for pre-dialysis CKD

Merck, known as MSD outside the United States and Canada, announced today that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) unanimously voted to recommend approval of Merck's VYTORIN (ezetimibe/simvastatin) for use in patients with pre-dialysis chronic kidney disease.

3 Nov 2011

Role of cardiovascular magnetic resonance in clinical cardiology

Cardiovascular Magnetic Resonance (CMR) has undergone substantial development and offers important advantages compared with other well-established imaging modalities.

3 Nov 2011

Exenatide's rapid anti-inflammatory effect may inhibit atherosclerosis

Exenatide, a drug commonly prescribed to help patients with type 2 diabetes improve blood sugar control, also has a powerful and rapid anti-inflammatory effect, a University at Buffalo study has shown.

3 Nov 2011

Abbott to highlight latest research findings on HUMIRA at ACR annual meeting

Abbott scientists and independent researchers will highlight the latest research findings on HUMIRA (adalimumab) at this year's American College of Rheumatology (ACR) Annual Scientific Meeting, scheduled for November 5-9 in Chicago.

3 Nov 2011

Link between eating nuts and higher levels of serotonin in MetS patients

For the first time, scientists report a link between eating nuts and higher levels of serotonin in the bodies of patients with metabolic syndrome (MetS), who are at high risk for heart disease.

3 Nov 2011

Eliminating senescent cells could prevent or delay onset of age-related disorders

Researchers at Mayo Clinic have shown that eliminating cells that accumulate with age could prevent or delay the onset of age-related disorders and disabilities. The study, performed in mouse models, provides the first evidence that these "deadbeat" cells could contribute to aging and suggests a way to help people stay healthier as they age.

3 Nov 2011

Replacing short auto trips with bicycle trips would yield major health benefits

Cutting out short auto trips and replacing them with mass transit and active transport would yield major health benefits, according to a study just published in the scientific journal Environmental Health Perspectives.

3 Nov 2011